Jul 20, 2020 12:10 PM IST
The Mumbai-based company reduced the price of FabiFlu to 75 rupees ($1.00) per tablet last week for restricted emergency use in patients with mild-to-moderate COVID-19 symptoms in India.
- Jul 13, 2020 12:40 PM IST
Glenmark completed the phase 3 clinical trial with Favipiravir (FabiFlu) in mild to moderate COVID-19 patients in India.
- Jul 01, 2020 09:52 AM IST
Glenmark allegedly conspired with pharmaceutical maker Apotex Corp and other generic drug companies to increase the prices of cholesterol medication pravastatin and other generic drugs, the department said.
- Jan 07, 2020 10:44 AM IST
Deferasirox is used to treat high levels of iron in the body caused by multiple blood transfusions.
- Nov 10, 2019 12:05 PM IST
According to the latest Enforcement Report by the US Food and Drug Administration (USFDA), Glenmark Pharmaceuticals Inc USA is recalling the product in various strengths which was manufactured at company's Goa manufacturing facility.
- Jun 24, 2019 10:36 AM IST
Glenmark said it will continue to pursue regulatory approval for Ryaltris and work closely with the FDA to determine the appropriate next steps
- Oct 15, 2018 04:00 PM IST
The product is a generic version of Sun Pharmaceutical Industries' Westcort Cream in the same strength, it added.
- Aug 07, 2017 03:11 PM IST
Axis Direct is bullish on Glenmark has recommended buy rating on the stock with a target price of Rs 840 in its research report dated August 02, 2017.
- May 15, 2017 11:34 AM IST
Titan's EBIT from the jewellery business is ten times the EBIT from watches plus eyewear business put together, said Udayan Mukherjee.
- May 11, 2017 10:39 PM IST
The profits were impacted due to an Rs 81 crore exceptional item, high expenses and decline in sales across Europe, Latin America, and other markets. The expenses shot up 13.6 percent to Rs 2152 crore on sequential basis.
- Mar 29, 2017 04:48 PM IST
Axis Direct is bullish on Glenmark Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1100 in its research report dated March 24, 2017.
- Mar 22, 2017 01:54 PM IST
Sudarshan Sukhani of s2analytics.com suggests selling Tata Motors and Glenmark Pharma and advises buying Colgate Palmolive.
- Mar 25, 2015 09:00 PM IST
Glenmark's medicines, Zita and Zita-Met, cost 30 percent less than MSD's Januvia and Janumet, which is due to the customs duty paid by the US firm, the High Court had said and added that "no allegation has been made that MSD on Wednesday sells its drugs at a relatively high price that hinders access to the drug".